These findings, together with the recent finding that FXR agonists protect against atherosclerosis [37], [38], [39], suggest that FXR is a potential therapeutic target for maintaining cholesterol homeostasis as well as for treatment of hypercholesterolemia and coronary heart disease. This evidence concerns the gene NR1H4 and familial hypercholesterolemia.